How is GeneDx managing the exome versus genome mix, especially given competitive pressures, while still providing the best service to customers?

Katherine Stueland stated that while genome is the future, exome testing diagnoses 80% of genetic diseases. GeneDx utilizes reflex testing to offer flexibility, allowing clinicians to start with exome and reflex to genome if needed, often with faster turnaround times than competitors' genome-only offerings. This 'meticulous approach' ensures customers receive appropriate technology. “If they need more information, then we can quickly reflex them beyond that exome to a genome. And because we've been able to drive down our turnaround times, we can do all of that faster than other labs can run a genome.”

Given the significant Carelon coverage expansion, when should we expect to see a financial benefit, particularly in Q3 or Q4?

Katherine Stueland and Kevin Feeley confirmed the Carelon expansion is a massive positive but reiterated that coverage leads and payment lags. They do not expect any impact in Q3, some contribution beginning in Q4 2026, but the 'more fully' realized benefit is anticipated in 2027 due to the time it takes for payers to operationalize policies and for collections to flow through. “coverage leads and payment lags. So there's just a massive opportunity ahead to raise our collection rates and revenue based on Carelon and extended coverage to about 56 million lives, but payers don't always operationalize everything immediately.”

Why did the blended average reimbursement rate (ARR) remain flat or slightly down in Q2, despite a significant improvement in the genome mix?

Kevin Feeley clarified that while the genome mix improved (from ~40% to 32%), exome collection rates were roughly flat, and there was slight variation in payer mix. He also explained that the 32% collection rate cited is specifically for *outpatient insurance-based volume*, excluding the 100% collected NICU volume, which buoys the overall rate. He stated that the Q2 blended ARR has stabilized and now serves as a new baseline. “The nuance there is those collection rates we cited are for the outpatient insurance-based volume only. And so what I mean by that is excluding the NICU, the NICU is collected at 100% and what buoys that rate back up towards the 50% range in total.”

WGS

GeneDx (WGS) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 3, 2026

Source: earnings call transcript

Executive summary

GeneDx Q2 FY26 — Record Volume and Return to Profitability

GeneDx delivered a solid Q2 FY26 with record test volumes and an earlier-than-expected return to profitability, driven by strong demand and completed cost actions. The company is now intensely focused on optimizing unit economics and improving collection rates, particularly for genome testing, which saw significant payer coverage expansion. Management expects meaningful improvements in collection rates and cash flow generation in Q4 FY26 and 2027.

Highlights

Achieved a record of over 30,000 exome and genome tests, representing 32% year-over-year growth.
Reported $114.4 million in total revenue, exceeding guidance for the quarter.
Returned to profitability one quarter earlier than expected, with adjusted net income of $0.4 million.
Commercial genome coverage expanded significantly from 47% to 87% in one quarter, primarily due to Carelon's new policy.
Completed the full $25 million in annual cost actions committed to on the last call.

Concerns

Outpatient genome collection rate remained approximately 32%, flat quarter-over-quarter and down from 43% in Q2 FY25.
Blended average reimbursement rate was $3,258 per test, roughly flat quarter-over-quarter.
Whole genome testing costs nearly twice as much to produce as exome, primarily due to higher reagent costs.

Guidance & targets

Category	Target	Timeline	Confidence
Full-year 2026 Revenue	$475M-$490M high materiality	FY26	High
Full-year 2026 Exome and Genome Volume Growth	at least 30% medium materiality	FY26	High
Full-year 2026 Exome and Genome Revenue Growth	at least 20% medium materiality	FY26	High
Full-year 2026 Gross Margin	approximately 70% medium materiality	FY26	High
Full-year 2026 Profitability	profitable for the full year high materiality	FY26	High
Q3 2026 Revenue	$122M-$124M high materiality	Q3 · FY26	High
Q3 2026 Exome and Genome Revenue	$110M-$112M medium materiality	Q3 · FY26	High
Q3 2026 Exome and Genome Volume	approximately 33,200 tests medium materiality	Q3 · FY26	High
Q3 2026 Blended Average Reimbursement Rate (ARR)	approximately $3,300 per test medium materiality	Q3 · FY26	High
Q3 2026 Gross Margin	approximately 70% medium materiality	Q3 · FY26	High
Q3 2026 Adjusted Net Income	approximately $2M high materiality	Q3 · FY26	High
Collection Rates Improvement	meaningful improvements high materiality	Q4 · FY26	Medium
Cost per Test	relatively flat low materiality	H2 FY26	Medium
Cash Flow Generation	returning to cash flow generation high materiality	Q4 · FY26	High
Genome Mix (insurance-based outpatient volume)	around 30%, maybe slightly lower low materiality	H2 FY26	Medium

Product announcements

Product	Type	Timeline	Details
1-minute genome ordering	launch	later this summer

Deals & partnerships

Blackstone Life Sciences Expansion of existing debt facility and concurrent equity investment $50M

Fortified financial position through a $50 million expansion of existing debt facility and a concurrent equity investment from Blackstone Life Sciences.

Risks & headwinds

Low Outpatient Collection Rates Current

Outpatient genome collection rate approximately 32%, flat QoQ and down from 43% in Q2 FY25.

Mitigation:Intense focus on improving revenue cycle management (RCM) processes, implementing payer-specific workflows, and investing in AI and technology to reach an industry standard of 70% collection rate.

Lag in Payment from Payer Coverage Expansion Near-term (Q3/Q4 FY26)

Commercial genome coverage expanded from 47% to 87% in Q2, but payment lags coverage.

Mitigation:Continued focus on RCM and operational effectiveness to translate expanded coverage into actual payment, with significant uplift expected in 2027.

High Cost of Whole Genome Production Current

Whole genome costs nearly twice as much to produce than exome, primarily due to higher reagent costs.

Mitigation:Expect costs to come down as utilization for genome grows and manufacturers advance their technology, with step improvements anticipated in 2027.

Administrative Barriers to Payment Current

Claims denied by overly restricted eligibility criteria and administrative barriers, even with written coverage policies.

Mitigation:Building payer-specific workflows to ensure compliance with medical necessity criteria, documentation requirements, and prior authorization processes to improve approval rates and reduce avoidable denials.

What to watch in Q3 FY26

Outpatient genome collection rate

Q4 FY26

Current ~32%

Target Meaningful improvement

Why it matters

This is a key driver for revenue uplift and profitability, with management targeting a 70% collection rate in the long term.

We expect to see meaningful improvements in Q4 2026 with the most significant uplift coming in 2027, as both expanded coverage and stronger operational execution compound together.

Find out whether WGS delivers this. Inve re-checks your case every morning.

Q&A highlights

Can you elaborate on the pacing of collection rate improvements in Q3 and Q4, and what the upside could mean for 2027?

Management explained that there's a natural lag between operational improvements and accrual rates. Q3 collection rates are expected to remain flat, with meaningful improvements beginning in Q4 2026 and significant upside in 2027. They emphasized that the current 32% genome collection rate reflects coverage maturity, not the target, and doubling it to 70% represents a substantial opportunity.

“Look, today, at 32% genome collection rates reflect where we are in the coverage maturity, not where we think we're going.”

asked by Dan Brennan · answered by Kevin Feeley

2 min read 5 chapters

Detailed narrative

Optimizing Unit Economics and Revenue Cycle Management

GeneDx is intensely focused on improving its blended average reimbursement rate, which is currently seen as underearning its potential. The strategy involves four key levers: mix management (shifting towards exome/reflex in the near term), expanding payer coverage (e.g., Carelon's significant expansion for genome), implementing payer-specific workflows to meet administrative requirements, and investing in AI and other technologies for revenue cycle operations.

These actions are expected to influence rates in the coming quarters, with meaningful improvements anticipated in Q4 FY26 and significant uplift in 2027.

Commercial Strategy and Market Diversification

The company maintains strong market leadership, holding approximately 80% market share among geneticists and expanding its pediatric neurology market share to roughly 50%. GeneDx is also strategically diversifying its call points by investing in general pediatrics, a channel that saw its highest growth ever in Q2.

This expansion is driven by changes in AAP guidelines and aims to unlock the total addressable market, bringing genomic testing to patients earlier in their diagnostic journey. The company adjusts coverage models to ensure appropriate return on investment for its sales force.

Payer Coverage Expansion and Lag in Payment

Significant progress was made in payer coverage, with commercial genome coverage expanding from 47% to 87% in Q2, primarily due to a new Carelon policy covering 56 million lives. Additionally, Medicaid coverage for exome/genome testing is now available in 39 states, with Mississippi coming online in July.

While these expansions represent a structural shift in reimbursement outlook, there is a natural lag between coverage and actual payment. The full impact on blended ARR and revenue is expected to flow through more significantly in 2027.

Collection Rate Opportunity and Operational Effectiveness

The outpatient genome collection rate stands at approximately 32%, a figure management views as a tremendous opportunity for improvement. This rate reflects the company's strategy to accept volume ahead of coverage to build clinical evidence. GeneDx aims to double this collection rate to an industry standard of 70%, which would significantly boost revenue and profitability.

Operational improvements, including new revenue cycle leaders and enhanced workflows, are being implemented, with their full impact expected to compound in 2027.

Financial Fortification and Capital Management

GeneDx fortified its financial position by expanding its existing debt facility by $50 million and securing a concurrent equity investment from Blackstone Life Sciences. This brings pro forma liquidity to approximately $188 million as of June 30, 2026, ensuring the company is fully capitalized well beyond sustained positive cash flow.

The company completed $25 million in annual cost actions and expects to return to cash flow generation in Q4 FY26, with strong sustained cash generation projected for 2027.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.